---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-424755"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2026-10-19T13:22:16+00:00"
generated_at: "2026-10-19T13:23:06.353747+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# EyePoint's DURAVYU misses Phase 3 LUCIA primary endpoint; 53% workforce cut, wet AMD trials halted

## Summary
- Phase 3 LUCIA study of DURAVYU in wet AMD did not meet the primary endpoint of non-inferiority, though vision improved and key secondary endpoints were met.
- EyePoint will conclude both pivotal Phase 3 wet AMD trials early, without completing year two, and cut approximately 53% of positions, mostly in Q4 2026, finishing in 1H 2027.
- Restructuring carries about $9M in severance and related charges but is expected to generate roughly $30M in annualized savings.
- Company estimates ~$118M in cash, cash equivalents and short-term investments as of September 30, 2026; figures are preliminary and unaudited.
- Resources now focus on DURAVYU in DME, with Phase 3 COMO and CAPRI (551 patients) topline data expected in Q4 2027; VERONA Phase 2 showed >70% supplement-free at six months.

## SEC filing metadata
- accession: 0001193125-26-424755
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2026-10-19T13:22:16+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 2.05, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000119312526424755/0001193125-26-424755-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000119312526424755/eypt-20261017.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-424755
- JSON: https://secwatch.observer/filing/0001193125-26-424755.json
- Plain text: https://secwatch.observer/filing/0001193125-26-424755.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.